Home・Stock List・AbbVie Inc

AbbVie Inc

Closed

SectorHealthcare

245.89 0.86

Buy Sell

Overview

Share price change

24h

Current

Min

244.4

Max

245.89

Key metrics
By Trading Economics
Income	2.9B 3.6B
Sales	2B 17B
P/E Sector Avg	69.237 68.51
EPS	3.65
Dividend yield	1.34
Profit margin	21.283
Employees	57,000
EBITDA	3B 6.7B

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+12.2% upside

Dividends
By Acuity
Dividend yield Sector Avg	1.34% 2.29%
Next Earnings	30 Oct 2026
Next Dividend date	14 Aug 2026
Next Ex Dividend date	14 Oct 2026

Market Stats
By TradingEconomics
Market Cap	-21B 433B
Previous open	245.03
Previous close	245.89

News Sentiment

By Acuity

51%

49%

242 / 340 Healthcare

AbbVie Inc Chart

Past performance is not a reliable indicator of future results.

Related News

7 Aug 2026, 23:01 UTC

AbbVie Inc shares are trading lower in after-market hours, with no specific news identified to explain the decline. The stock remains near its one-month low.

6 Aug 2026, 20:06 UTC

Social Media

AbbVie Inc shares are lower as bearish sentiment grows in biotech and pharma sectors, with discussions highlighting potential resistance and negative momentum patterns.

5 Aug 2026, 19:26 UTC

News

Event

AbbVie shares are higher as Canada's Drug Agency recommends UBRELVY for migraine treatment. The company also raised its 2026 revenue outlook to $67.60 billion.

4 Aug 2026, 23:01 UTC

Event

AbbVie Inc shares are higher in after-market hours following a recommendation for UBRELVY® reimbursement by Canada's Drug Agency, enhancing patient accessibility.

3 Aug 2026, 23:06 UTC

News

Canaccord Genuity raised its price target for AbbVie to $290, contributing to a modest increase in shares during after-market hours.

31 Jul 2026, 20:04 UTC

News

Event

AbbVie Inc. lowered its 2026 adjusted earnings guidance, now projecting $13.87 to $14.07 per share, contributing to a decline in its stock price today.

30 Jul 2026, 22:41 UTC

Social Media

Event

AbbVie Inc announced JUVÉDERM® Day for August 19, 2026, boosting shares higher in after-market hours amid strong trading activity.

29 Jul 2026, 23:06 UTC

Event

The European Commission approved RINVOQ® for severe alopecia areata, contributing to higher after-market hours trading for Abbvie Inc. Shares remain above their 20-day moving average.

28 Jul 2026, 23:06 UTC

AbbVie Inc. shares traded higher in after-market hours, remaining above the 20-day moving average and near the upper end of their one-month range.

27 Jul 2026, 19:46 UTC

Social Media

AbbVie Inc. shares are trading lower amid a broader market decline, influenced by falling crude oil prices despite recent social media discussions on its 52-week high.

24 Jul 2026, 23:51 UTC

Social Media

Abbvie shares are trading lower in after-market hours despite a presentation on ABBV-CLS-484, a novel cancer immunotherapy inhibitor.

23 Jul 2026, 10:16 UTC

AbbVie Inc shares are trading lower in pre-market hours, with no specific news identified to explain the movement. The stock remains within its one-month trading range.

22 Jul 2026, 23:06 UTC

AbbVie Inc shares are modestly higher in after-market trading. No specific news was identified to explain the movement, amid broader market volatility.

21 Jul 2026, 19:06 UTC

Abbvie Inc. is higher today, supported by broader market gains and optimism in the semiconductor sector after TSMC's potential price increases by 2027.

20 Jul 2026, 23:01 UTC

AbbVie Inc. shares are lower in after-hours trading following a decline from earlier gains, remaining above the 20-day moving average.

Peer Comparison

Price change

AbbVie Inc Forecast

Price Target

By TipRanks

12.2% upside

12 Months Forecast

Average 276.05 USD 12.2%

High 300 USD

Low 225 USD

Based on 23 Wall Street analysts offering 12 month price targets forAbbVie Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

23 ratings

Buy

Hold

Sell

Based on 23 analysts giving stock ratings to AbbVie Inc - Dist in the past 3 months.

Sentiment

By Acuity

242 / 340 Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About AbbVie Inc

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; Evolveimmune Therapeutics, Inc.; Genentech, Inc.; AbCellera Biologics Inc.; and Tentarix Biotherapeutics, LP. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.